Digoxin: Na+/K+ ATPase Inhibitor for Cardiac & Antiviral Research

Executive Summary: Digoxin is a high-purity cardiac glycoside used to inhibit the Na+/K+ ATPase pump, thereby enhancing cardiac contractility in experimental heart failure models (product information). In vitro, it impairs chikungunya virus (CHIKV) infection in select human cells with dose-dependent efficacy from 0.01–10 μM, but not in murine or mosquito lines (related article). Supplied as a solid (molecular weight: 780.94, C41H64O14), Digoxin is soluble in DMSO (≥33.25 mg/mL) but insoluble in water or ethanol, requiring light-protected storage at 4°C. APExBIO verifies product purity (>98%) by HPLC and NMR, supporting consistent research outcomes. Animal studies confirm its ability to decrease right atrial pressure and increase cardiac output in canine heart failure models (mechanistic review).

Biological Rationale

Digoxin is a clinically established cardiac glycoside for heart failure and arrhythmia research, valued for its defined mechanism and reproducibility across models. Its primary action is inhibition of the Na+/K+ ATPase pump, which is essential for maintaining electrochemical gradients in cardiomyocytes and other excitable cells. Inhibition causes increased intracellular sodium, which elevates intracellular calcium via the sodium-calcium exchanger, directly enhancing myocardial contractility. This mechanism has been leveraged in both preclinical and translational studies of heart failure and arrhythmia (cardiac/antiviral bridge). Recent in vitro work reveals that Digoxin can also disrupt the replication cycle of chikungunya virus by targeting host cell ionic homeostasis, but only in specific human-derived cells, not in murine or vector models (article).

Mechanism of Action of Digoxin

Digoxin binds to and inhibits the Na+/K+ ATPase pump on the plasma membrane of animal cells. This inhibition increases intracellular sodium concentration, reducing the activity of the sodium-calcium exchanger. As a result, intracellular calcium rises, enhancing force of contraction in cardiac cells. This classic mechanism underpins its utility in congestive heart failure and arrhythmia models (APExBIO). In the context of chikungunya virus infection, Digoxin-mediated ionic disruption impairs viral replication in a cell-type- and dose-dependent manner, with maximal inhibition observed between 0.01 and 10 μM in human osteosarcoma (U-2 OS) and primary synovial fibroblasts (anti-trop2 summary). This effect is not replicated in murine or mosquito cells, highlighting species selectivity.

Evidence & Benchmarks

• Digoxin increases cardiac output and lowers right atrial pressure in canine models of congestive heart failure when dosed intravenously at 1–1.2 mg (APExBIO product).
• In vitro, Digoxin inhibits chikungunya virus (CHIKV) infection in U-2 OS, primary human synovial fibroblasts, and Vero cells, with dose-dependent efficacy from 0.01–10 μM (mechanistic summary).
• Digoxin is insoluble in water and ethanol but achieves ≥33.25 mg/mL solubility in DMSO, facilitating preparation for cell-based assays (product specs).
• The supplied compound has a molecular weight of 780.94, is typically >98% pure (HPLC/NMR), and is stored at 4°C protected from light (APExBIO).
• Antiviral effects are cell-type specific; no reduction in CHIKV infection is seen in murine or mosquito (vector) cells (internal article).
• Digoxin does not inhibit viral infection mechanisms outside Na+/K+ ATPase-dependent pathways (protocol review).

Applications, Limits & Misconceptions

Digoxin is primarily deployed in preclinical cardiac studies and arrhythmia treatment research, as well as in select antiviral workflows targeting CHIKV in human cells. Its robust purity and defined solubility parameters support reproducibility in in vitro and animal model workflows. However, its antiviral efficacy is limited to certain cell types, and it does not demonstrate broad-spectrum antiviral activity. Digoxin is not effective in models lacking Na+/K+ ATPase-dependent viral entry or replication pathways. For a deeper exploration of mechanistic and translational nuances, see Digoxin in Translational Research, which details comparative protocols and workflow integration beyond this summary.

Common Pitfalls or Misconceptions

• Assuming Digoxin is broadly antiviral—its effect is cell-type and virus-specific (internal review).
• Overlooking solubility constraints—Digoxin is not water- or ethanol-soluble and must be dissolved in DMSO for assays (product info).
• Expecting efficacy in murine or mosquito models—antiviral activity is not seen in these species (evidence).
• Using solutions stored long-term—stability drops; fresh solutions are recommended for experimental accuracy (storage guidelines).
• Assuming mechanism of action extends beyond Na+/K+ ATPase inhibition—Digoxin does not target alternative viral or cardiac pathways (mechanism review).

Workflow Integration & Parameters

• Compound preparation: Dissolve Digoxin in DMSO to ≥33.25 mg/mL; do not use water or ethanol (APExBIO).
• Storage: Store solid at 4°C protected from light; prepare fresh solutions for each experiment for maximal stability.
• In vitro antiviral assays: Use 0.01–10 μM for dose-response in human cell lines; do not extrapolate to murine/vector models (protocols).
• Animal cardiovascular models: For canine CHF, intravenous doses of 1–1.2 mg have been validated for hemodynamic changes (product sheet).
• Purity validation: Use only batches with >98% HPLC/NMR confirmation to ensure reproducibility.

Conclusion & Outlook

Digoxin remains a cornerstone Na+/K+ ATPase pump inhibitor for both cardiac and select antiviral research workflows. Its established mechanism, cell-type-selective antiviral activity, and high formulation purity facilitate translational studies in heart failure and chikungunya virus models. While its applications are robust in defined domains, Digoxin’s selectivity must be carefully considered. For extended discussion on translational integration and workflow strategy, see the updated review (Digoxin at the Translational Frontier), which elaborates on the interface between mechanistic and applied research. APExBIO’s Digoxin (SKU B7684) offers a validated, high-purity reagent for reproducible mechanistic and translational studies.